Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
February 28 2023 - 4:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
participation in the 43rd Annual Cowen Health Care Conference,
taking place March 6-8, 2023, in Boston, Massachusetts.
Kronos Bio President and Chief Executive Officer
Norbert Bischofberger, Ph.D., will participate in the “Novel
Oncology Targets” panel discussion on Tuesday, March 7, at 9:10
a.m. ET.
The webcast of the panel discussion will be
available on the Investors and Media section of the
Kronos Bio website at www.kronosbio.com. A replay of the
webcast will be archived and available for 30 days following the
event.
About Kronos Bio, Inc.Kronos Bio is a
biopharmaceutical company that is advancing two investigational
compounds in clinical trials for patients with cancer. The company
is developing the CDK9 inhibitor, KB-0742, as a treatment
for MYC-amplified solid tumors, and lanraplenib, a
next-generation SYK inhibitor, for patients with
relapsed/refractory FLT3-mutated acute myeloid leukemia. The
company’s scientific focus is on developing medicines that target
the dysregulated transcription that is the hallmark of cancer and
other serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research
facility in Cambridge, Mass. For more information, visit
www.kronosbio.com or follow the company on LinkedIn.
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jul 2023 to Jul 2024